Loading...
XNASLXRX
Market cap276mUSD
Jan 10, Last price  
0.77USD
1D
-10.86%
1Q
-55.97%
Jan 2017
-94.46%
Name

Lexicon Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:LXRX chart
P/E
—
P/S
230.05
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.88%
Rev. gr., 5y
-54.71%
Revenues
1m
+766.19%
61,740,00075,680,00072,798,00050,118,00032,321,00010,700,0004,908,0001,849,0001,089,0002,222,00022,854,000130,014,00083,337,00090,335,00063,209,000322,073,00023,995,000298,000139,0001,204,000
Net income
-177m
L+71.75%
-47,172,000-36,315,000-54,311,000-58,794,000-76,860,000-82,780,000-101,775,000-116,215,000-110,211,000-104,126,000-100,294,000-4,682,000-141,429,000-129,050,000-120,548,000130,133,000-70,184,000-88,268,000-103,128,000-177,119,000
CFO
-162m
L+82.21%
-42,256,00023,442,000-56,909,000-74,323,000-95,600,000-89,016,000-82,368,000-87,938,000-94,460,000-91,079,000-75,622,000184,776,000-175,628,000-185,394,000-148,607,000113,807,000-142,969,000-87,017,000-88,851,000-161,897,000
Earnings
Mar 10, 2025

Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
URL
https://www.lexpharma.com/
IPO date
Apr 07, 2000
Employees
135
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,204
766.19%
139
-53.36%
Cost of revenue
58,972
101,326
Unusual Expense (Income)
NOPBT
(57,768)
(101,187)
NOPBT Margin
Operating Taxes
1,184
Tax Rate
NOPAT
(57,768)
(102,371)
Net income
(177,119)
71.75%
(103,128)
16.84%
Dividends
Dividend yield
Proceeds from repurchase of equity
137,999
93,341
BB yield
-40.79%
-29.49%
Debt
Debt current
1,291
1,291
Long-term debt
110,038
60,718
Deferred revenue
Other long-term liabilities
Net debt
(58,697)
(76,348)
Cash flow
Cash from operating activities
(161,897)
(88,851)
CAPEX
(470)
(1,326)
Cash from investing activities
(49,943)
(71,078)
Cash from financing activities
187,960
142,209
FCF
(63,208)
(103,266)
Balance
Cash
170,026
138,357
Long term investments
Excess cash
169,966
138,350
Stockholders' equity
(1,766,563)
(1,589,959)
Invested Capital
1,965,737
55,533
ROIC
ROCE
EV
Common stock shares outstanding
221,130
165,733
Price
1.53
-19.90%
1.91
-51.52%
Market cap
338,329
6.88%
316,550
-44.84%
EV
279,632
240,202
EBITDA
(57,214)
(100,760)
EV/EBITDA
Interest
13,101
2,780
Interest/NOPBT